T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference
LEXINGTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted four new studies supporting the T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel that were recently presented at the IDWeek conference in Boston, Massachusetts.
- LEXINGTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted four new studies supporting the T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel that were recently presented at the IDWeek conference in Boston, Massachusetts.
- The data demonstrates the speed, accuracy and clinical benefits of the T2Dx® Instrument and T2 Biosystems’ sepsis panels and early analytical data on the T2Resistance Panel.
- “We are encouraged by our latest clinical results as they showcase the critical detection capabilities of both our instrument and sepsis test panels.
- Adding to our clinical data library and increasing awareness of the clinical and economic benefits of our technology is an important part of our commercial strategy," said John Sperzel, Chairman and CEO of T2 Biosystems.